ANX-514

ANX-514 is a detergent-free, nano-emulsion reformulation of the taxane chemotherapy drug docetaxel. Developed by Mast Therapeutics (formerly Adventrx Pharmaceuticals), it was designed to eliminate the need for polysorbate 80 (Tween 80), a detergent used in the standard docetaxel formulation (Taxotere) that is frequently associated with severe hypersensitivity reactions and requires corticosteroid premedication. ANX-514 was intended to improve the safety profile and patient convenience of docetaxel therapy by delivering the active ingredient in a novel nano-emulsion. However, the program was discontinued after a pivotal Phase 1 bioequivalence study in patients with advanced cancer failed to meet its primary pharmacokinetic endpoints in 2009, as the formulation did not demonstrate bioequivalence to Taxotere.

Other names

docetaxel for injectable emulsiondocetaxel nano-emulsion